Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
5 |
24/02/21 |
24/02/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
9 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
413
|
166K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
3 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
413
|
166K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
4 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
413
|
166K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
11 |
19/02/21 |
19/02/21 |
Charts
|
5.9K
|
2.3M
|
11
|
|
Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
19 |
19/02/21 |
19/02/21 |
Charts
|
5.9K
|
2.3M
|
19
|
|
Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
7 |
19/02/21 |
19/02/21 |
Charts
|
5.9K
|
2.3M
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
8 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
79
|
24K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
13 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
79
|
24K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
4 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
79
|
24K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
2 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
79
|
24K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
2 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
79
|
24K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
0 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
79
|
24K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
6 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
79
|
24K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP meeting with US FDA granted for ATL1102 in DMD
|
|
Crankbait
|
79 |
24K |
10 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
79
|
24K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Webinar - Antisense Therapeutics CEO
|
|
Crankbait
|
5 |
2.5K |
16 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
5
|
2.5K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Webinar - Antisense Therapeutics CEO
|
|
Crankbait
|
5 |
2.5K |
7 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
5
|
2.5K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Protein testing
|
|
Crankbait
|
13 |
2.8K |
3 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
13
|
2.8K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Protein testing
|
|
Crankbait
|
13 |
2.8K |
3 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
13
|
2.8K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Protein testing
|
|
Crankbait
|
13 |
2.8K |
1 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
13
|
2.8K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Protein testing
|
|
Crankbait
|
13 |
2.8K |
0 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
13
|
2.8K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Protein testing
|
|
Crankbait
|
13 |
2.8K |
2 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
13
|
2.8K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
2 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
413
|
166K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
0 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
413
|
166K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
0 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
413
|
166K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
0 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
413
|
166K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
0 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
413
|
166K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
0 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
413
|
166K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
2 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
413
|
166K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
Crankbait
|
37 |
12K |
1 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
37
|
12K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
Crankbait
|
37 |
12K |
3 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
37
|
12K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
1 |
16/01/21 |
16/01/21 |
ASX - By Stock
|
413
|
166K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
1 |
16/01/21 |
16/01/21 |
ASX - By Stock
|
413
|
166K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
2 |
16/01/21 |
16/01/21 |
ASX - By Stock
|
413
|
166K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
2 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
413
|
166K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Crankbait
|
413 |
166K |
2 |
14/01/21 |
14/01/21 |
ASX - By Stock
|
413
|
166K
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
1 |
14/01/21 |
14/01/21 |
Charts
|
5.9K
|
2.3M
|
1
|
|
Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
0 |
14/01/21 |
14/01/21 |
Charts
|
5.9K
|
2.3M
|
0
|
|
Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
11 |
14/01/21 |
14/01/21 |
Charts
|
5.9K
|
2.3M
|
11
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Submits US Orphan Drug application for ATL1102 in DMD
|
|
Crankbait
|
60 |
21K |
5 |
24/08/20 |
24/08/20 |
ASX - By Stock
|
60
|
21K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: EMA DMD Scientific Advice and Regulatory Process Update
|
|
Crankbait
|
74 |
17K |
2 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
74
|
17K
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
Crankbait
|
5.9K |
2.3M |
1 |
10/07/20 |
10/07/20 |
Charts
|
5.9K
|
2.3M
|
1
|
|
ASX - By Stock
|
PER |
Re:
Video Interview with Mark Diamond
|
|
Crankbait
|
39 |
9.2K |
5 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
39
|
9.2K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Video Interview with Mark Diamond
|
|
Crankbait
|
39 |
9.2K |
2 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
39
|
9.2K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Crankbait
|
116 |
35K |
0 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
116
|
35K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Crankbait
|
116 |
35K |
2 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
116
|
35K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Crankbait
|
116 |
35K |
4 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
116
|
35K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Crankbait
|
116 |
35K |
3 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
116
|
35K
|
3
|
|
ASX - By Stock
|
PER Biotech |
Re:
USA ANP
|
|
Crankbait
|
38 |
14K |
11 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
38
|
14K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change in substantial holding from AEF
|
|
Crankbait
|
116 |
35K |
1 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
116
|
35K
|
1
|
|